How Nexopamil racemate can Save You Time, Stress, and Money.
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate multiple intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Major trial aims were being To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis